. List of genes for a targeted exon sequencing analysis. 1  MYO1B  31  100%  31  0  NCOA3  21  100%  21  0  NCOR1  47  99%  46  1  NEB  183  92%  168  15  NEFH  4  97%  4  0  NF1  60  100%  59  1  NF2  17  100%  17  0  NOTCH1  34  100%  34  0  NOTCH2  38  99%  37  1  NRAS  4  100%  4  0  ODZ1  32  100%  32  0  PDGFRA  24  100%  24  0  PIK3CA  20  99%  18  2  PIK3R1  19  100%  19  0  PKHD1  69  100%  69  0  PTCH1  27  100%  27  0  PTEN  9  100%  9  0  PTPN11  16  97%  15  1  PTPN12  20  100%  20  0  RB1  27  100%  27  0  RELN  66  100%  66  0  RET  20  99%  19  1  RNF43  9  100%  9  0  ROS1  45  100%  45  0  RUNX1  12  97%  11  1  RYR1  106  100%  106  0  RYR2  111  100%  110  1  RYR3  107  100%  106  1  SETD2  27  100%  27  0  SMAD1  6  100%  6  0  SMAD2  10  100%  10  0  SMAD3  10  100%  10  0   SMAD4   13  100%  13  0  SMARCA4  39  100%  39  0  SOX9  3  100%  3  0  STK11  9  100%  9  0  SYNE1  151  100%  151  0  TCERG1  22  100%  22  0  TCF7L2  18  100%  18  0  TGFBR1  10  100%  10  0  TGFBR2  9  100%  9  0  TP53  14  98%  13  1  TSHR  11  100%  11  0  TTN  364  99%  345  19  USH2A  72  100%  72  0  VHL  3  99%  3  0  WT1  11  100%  11  0  ZFHX4  13  99%  12  1 The list of 126 candidate cancer driver genes analyzed in target exon sequencing and coverage information are shown.
Supplementary Figure S4 . 13 Comparison of somatic mutations between high-methylation CRC, SSA/P and TSA. 14 The frequency of somatic mutations was significantly higher in high-methylation CRC 15 than in SSA/P or TSA, both in indels (21.0 ± 4.5 vs 5.1 ± 2.7 for SSA/P, P<0.0001, and 16 vs 4.5 ± 2.3 for TSA, P<0.0001), and in non-synonymous (missense and nonsense) 17 mutations (282.3 ± 27.5 vs 245.7 ± 19.3 for SSA/P, P<0.0001, and vs 232.7 ± 17.4 for 18 TSA, P=0.001). However, the frequency of somatic mutations was not significantly 19 different between MLH1-methylated and MLH1-unmethylated SSA/P (247.2 ± 20.1 vs 1 Supplementary Figure S7 . focal loss of MLH1 protein was detected in these two MLH1-methylated SSA/P samples. 
